Abstract
Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 22-29 |
| Number of pages | 8 |
| Journal | Cancer Investigation |
| Volume | 20 |
| Issue number | SUPPL. 2 |
| State | Published - Nov 21 2002 |
| Externally published | Yes |
Fingerprint
Keywords
- Anthracycline
- Chemotherapy
- Doxorubicin
- Drug delivery
- Liposome
- Metastatic breast cancer
- Pegylated liposomal doxorubicin
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer : The Cancer Research Network, Inc., experience. / Perez, Alejandra; Domenech, Gabriel H.; Frankel, Cynthia; Vogel, Charles.
In: Cancer Investigation, Vol. 20, No. SUPPL. 2, 21.11.2002, p. 22-29.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer
T2 - The Cancer Research Network, Inc., experience
AU - Perez, Alejandra
AU - Domenech, Gabriel H.
AU - Frankel, Cynthia
AU - Vogel, Charles
PY - 2002/11/21
Y1 - 2002/11/21
N2 - Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.
AB - Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.
KW - Anthracycline
KW - Chemotherapy
KW - Doxorubicin
KW - Drug delivery
KW - Liposome
KW - Metastatic breast cancer
KW - Pegylated liposomal doxorubicin
UR - http://www.scopus.com/inward/record.url?scp=0036420885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036420885&partnerID=8YFLogxK
M3 - Article
C2 - 12442346
AN - SCOPUS:0036420885
VL - 20
SP - 22
EP - 29
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - SUPPL. 2
ER -